

Second Nature

sek'and nā'chər. *An acquired habit so deeply ingrained as to be automatic and part of a person's nature.*

Second nature comes from ease of use.


To become a second-nature tool, an object must possess certain qualities.

Simplicity. Functionality. Portability.

They are part and parcel of many tools that make our life easier and better.

Tools such as the GLUCOSCAN™ 3000 Personal Blood Glucose Meter.

Simple



Everything can be learned, but simple things are learned more easily. Almost everyone knows how to use a paper clip.

The GLUCOSCAN 3000 Meter has precisely the kind of simplicity that invites easy learning.

Like the simple procedure. The simple two-touch operation. Or the permanent factory calibration that does away with both unnecessary steps and operator errors.

The faster the learning, the easier your training job. And the greater the likelihood of continued use.

The GLUCOSCAN one-minute test and dry-blot procedure make compliance sure and simple.

And when your patients comply, you can feel confident with their treatment program.

Functional

Functional tools work small miracles every day. Using a pencil has become second nature to the degree that its brilliant, functional design is taken for granted.

The GLUCOSCAN 3000 Meter can become just such a tool for your

patients. It is packed with functional features that make testing easy and appropriate for every lifestyle.

Like the Memory Bank™ Data Log that automatically stores your patient's last 29 test readings.

Or the largest, easiest-to-read digital display in glucose monitoring. The only adjustable volume control. The longest battery life. And the longest meter warranty — three full years — included free of extra charge.

Portable

Cumbersome objects stay home. Compact ones go places. When we wear a wristwatch, we always know the time no matter where we are.

Equally, with the GLUCOSCAN 3000 Meter, your patients can test their blood sugars virtually anywhere, because the GLUCOSCAN 3000 Meter is the smallest one available.



But of what use is a small meter if all the other testing supplies are not readily at hand? The unique, truly pocket-portable GLUCOSCAN

case holds everything required for on-the-go monitoring: Individually foil-wrapped GLUCOSCAN Test Strips, PENLET™ Automatic Blood Sampling Pen, GLUCOSCAN Lancets, and, of course, the GLUCOSCAN Meter itself.

GLUCOSCAN 3000

GLUCOSCAN 3000 is more than just another meter. It's an important part of life for many people.


Some say it's second nature.

Discover how blood glucose testing can become second nature with the GLUCOSCAN 3000 Personal Blood Glucose Meter. Call us toll-free for the name of your nearest Authorized LifeScan Distributor: Nationwide (800) 227-8862; in California (800) 982-6132.

Also available in the economical GLUCOSCAN 2000 model (Memory Bank not included).

LIFESCAN INC.
Mountain View, CA 94043

Now
even easier
with
Countdown
Start



Shown
actual size

GLUCOSCAN™ Meters

Easiest to start with.
Easiest to stay with.



TIMING IS KEY



EVERYTHING



Effective control time and time again¹

Effective control of fasting and postprandial glucose—patient after patient, meal after meal, year after year.

Insulin when it's needed

Insulin levels are rapidly elevated in response to a meal, then return promptly to basal levels after the meal challenge subsides.

Timed to minimize risks

Rapidly metabolized and excreted, with an excellent safety profile.¹ As with all sulfonylureas, hypoglycemia may occur.

In concert with diet in non-insulin-dependent diabetes mellitus

Glucotrol[®]
(glipizide) 5-mg and 10-mg
Scored Tablets 

**SYNCHRONIZED
SULFONYLUREA THERAPY**



Please see brief summary of Glucotrol[®] (glipizide) prescribing information on next page.

ROERIG 
A division of Pfizer Pharmaceuticals
New York, New York 10017

Reference:

1. Sachs R, Frank M, Fishman SK. Overview of clinical experience with glipizide. in *Glipizide: A Worldwide Review*. Princeton, NJ, Excerpta Medica, 1984. pp 163-172.

GLUCOTROL® (glipizide) Tablets

Brief Summary of Prescribing Information

INDICATIONS AND USAGE: GLUCOTROL is indicated as an adjunct to diet for the control of hyperglycemia in patients with non-insulin-dependent diabetes mellitus (NIDDM, type II) after an adequate trial of dietary therapy has proved unsatisfactory.

CONTRAINDICATIONS: GLUCOTROL is contraindicated in patients with known hypersensitivity to the drug or with diabetic ketoacidosis, with or without coma, which should be treated with insulin.

SPECIAL WARNING ON INCREASED RISK OF CARDIOVASCULAR MORTALITY: The administration of oral hypoglycemic drugs has been reported to be associated with increased cardiovascular mortality as compared to treatment with diet alone or diet plus insulin. This warning is based on the study conducted by the University Group Diabetes Program (UGDP), a long-term prospective clinical trial designed to evaluate the effectiveness of glucose-lowering drugs in preventing or delaying vascular complications in patients with non-insulin-dependent diabetes. The study involved 823 patients who were randomly assigned to one of four treatment groups (*Diabetes 19, supp. 2:747-830, 1970*).

UGDP reported that patients treated for 5 to 8 years with diet plus a fixed dose of tolbutamide (1.5 grams per day) had a rate of cardiovascular mortality approximately 2-1/2 times that of patients treated with diet alone. A significant increase in total mortality was not observed, but the use of tolbutamide was discontinued based on the increase in cardiovascular mortality, thus limiting the opportunity for the study to show an increase in overall mortality. Despite controversy regarding the interpretation of these results, the findings of the UGDP study provide an adequate basis for this warning. The patient should be informed of the potential risks and advantages of GLUCOTROL and of alternative modes of therapy.

Although only one drug in the sulfonylurea class (tolbutamide) was included in this study, it is prudent from a safety standpoint to consider that this warning may also apply to other oral hypoglycemic drugs in this class, in view of their close similarities in mode of action and chemical structure.

PRECAUTIONS: Renal and Hepatic Disease: The metabolism and excretion of GLUCOTROL may be slowed in patients with impaired renal and/or hepatic function. Hypoglycemia may be prolonged in such patients should it occur.

Hypoglycemia: All sulfonylureas are capable of producing severe hypoglycemia. Proper patient selection, dosage and instructions are important to avoid hypoglycemia. Renal or hepatic insufficiency may increase the risk of hypoglycemic reactions. Elderly, debilitated, or malnourished patients and those with adrenal or pituitary insufficiency are particularly susceptible to the hypoglycemic action of glucose-lowering drugs. Hypoglycemia may be difficult to recognize in the elderly or people taking beta-adrenergic blocking drugs. Hypoglycemia is more likely to occur when caloric intake is deficient, after severe or prolonged exercise, when alcohol is ingested, or when more than one glucose-lowering drug is used.

Loss of Control of Blood Glucose: A loss of control may occur in diabetic patients exposed to stress such as fever, trauma, infection or surgery. It may then be necessary to discontinue GLUCOTROL and administer insulin.

Laboratory Tests: Blood and urine glucose should be monitored periodically. Measurement of glycosylated hemoglobin may be useful.

Information for Patients: Patients should be informed of the potential risks and advantages of GLUCOTROL, of alternative modes of therapy, as well as the importance of adhering to dietary instructions, of a regular exercise program, and of regular testing of urine and/or blood glucose. The risks of hypoglycemia, its symptoms and treatment, and conditions that predispose to its development should be explained to patients and responsible family members. Primary and secondary failure should also be explained.

Drug Interactions: The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including non-steroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents. *In vitro* studies indicate that GLUCOTROL binds differently than tolbutamide and does not interact with salicylate or dicumarol. However, caution must be exercised in extrapolating these findings to a clinical situation. Certain drugs tend to produce hyperglycemia and may lead to loss of control, including the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. A potential interaction between oral miconazole and oral hypoglycemic agents leading to severe hypoglycemia has been reported. Whether this interaction also occurs with the intravenous, topical, or vaginal preparations of miconazole is not known.

Carcinogenesis, Mutagenesis, Impairment of Fertility: A 20-month study in rats and an 18-month study in mice at doses up to 75 times the maximum human dose revealed no evidence of drug-related carcinogenicity. Bacterial and *in vivo* mutagenicity tests were uniformly negative. Studies in rats of both sexes at doses up to 75 times the human dose showed no effects on fertility.

Pregnancy: Pregnancy Category C. GLUCOTROL (glipizide) was found to be mildly fetotoxic in rat reproductive studies at all dose levels (5-50 mg/kg). This fetotoxicity has been similarly noted with other sulfonylureas, such as tolbutamide and tolazamide. The effect is perinatal and believed to be directly related to the pharmacologic (hypoglycemic) action of GLUCOTROL. In studies in rats and rabbits no teratogenic effects were found. There are no adequate and well-controlled studies in pregnant women. GLUCOTROL should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Because recent information suggests that abnormal blood glucose levels during pregnancy are associated with a higher incidence of congenital abnormalities, many experts recommend that insulin be used during pregnancy to maintain blood glucose levels as close to normal as possible.

Nonteratogenic Effects: Prolonged severe hypoglycemia has been reported in neonates born to mothers who were receiving a sulfonylurea drug at the time of delivery. This has been reported more frequently with the use of agents with prolonged half-lives. GLUCOTROL should be discontinued at least one month before the expected delivery date.

Nursing Mothers: Since some sulfonylurea drugs are known to be excreted in human milk, insulin therapy should be considered if nursing is to be continued.

Pediatric Use: Safety and effectiveness in children have not been established.

ADVERSE REACTIONS: In controlled studies, the frequency of serious adverse reactions reported was very low. Of 702 patients, 11.8% reported adverse reactions and in only 1.5% was GLUCOTROL discontinued.

Hypoglycemia: See PRECAUTIONS and OVERDOSAGE sections.

Gastrointestinal: Gastrointestinal disturbances, the most common, were reported with the following approximate incidence: nausea and diarrhea, one in 70; constipation and gastralgia, one in 100. They appear to be dose-related and may disappear on division or reduction of dosage. Cholestatic jaundice may occur rarely with sulfonylureas; GLUCOTROL should be discontinued if this occurs.

Dermatologic: Allergic skin reactions including erythema, morbilliform or maculopapular eruptions, urticaria, pruritus, and eczema have been reported in about one in 70 patients. These may be transient and may disappear despite continued use of GLUCOTROL, if skin reactions persist, the drug should be discontinued. Porphyria cutanea tarda and photosensitivity reactions have been reported with sulfonylureas.

Hematologic: Leukopenia, agranulocytosis, thrombocytopenia, hemolytic anemia, aplastic anemia, and pancytopenia have been reported with sulfonylureas.

Metabolic: Hepatic porphyria and disulfiram-like alcohol reactions have been reported with sulfonylureas. Clinical experience to date has shown that GLUCOTROL has an extremely low incidence of disulfiram-like reactions.

Endocrine Reactions: Cases of hyponatremia and the syndrome of inappropriate antidiuretic hormone (SIADH) secretion have been reported with this and other sulfonylureas.

Miscellaneous: Dizziness, drowsiness, and headache have each been reported in about one in fifty patients treated with GLUCOTROL. They are usually transient and seldom require discontinuance of therapy.

OVERDOSAGE: Overdosage of sulfonylureas including GLUCOTROL can produce hypoglycemia. If hypoglycemic coma is diagnosed or suspected, the patient should be given a rapid intravenous injection of concentrated (50%) glucose solution. This should be followed by a continuous infusion of a more dilute (10%) glucose solution at a rate that will maintain the blood glucose at a level above 100 mg/dL. Patients should be closely monitored for a minimum of 24 to 48 hours since hypoglycemia may recur after apparent clinical recovery. Clearance of GLUCOTROL from plasma would be prolonged in persons with liver disease. Because of the extensive protein binding of GLUCOTROL (glipizide), dialysis is unlikely to be of benefit.

DOSAGE AND ADMINISTRATION: There is no fixed dosage regimen for the management of diabetes mellitus with GLUCOTROL. In general, it should be given approximately 30 minutes before a meal to achieve the greatest reduction in postprandial hyperglycemia.

Initial Dose: The recommended starting dose is 5 mg before breakfast. Geriatric patients or those with liver disease may be started on 2.5 mg. Dosage adjustments should ordinarily be in increments of 2.5-5 mg, as determined by blood glucose response. At least several days should elapse between titration steps.

Maximum Dose: The maximum recommended total daily dose is 40 mg.

Maintenance: Some patients may be effectively controlled on a once-a-day regimen, while others show better response with divided dosing. Total daily doses above 15 mg should ordinarily be divided.

HOW SUPPLIED: GLUCOTROL is available as white, dye-free, scored diamond-shaped tablets imprinted as follows: 5 mg tablet—Pfizer 411 (NDC 5 mg 0049-4110-66) Bottles of 100; 10 mg tablet—Pfizer 412 (NDC 10 mg 0049-4120-66) Bottles of 100.

CAUTION: Federal law prohibits dispensing without prescription.

More detailed professional information available on request.

ROERIG



A division of Pfizer Pharmaceuticals
New York, New York 10017

**FIGHT
HEART
DISEASE,
KIDNEY
DISEASE
AND
BLINDNESS.**

Support
the American
Diabetes
Association.

Diabetes is a major contributor to heart disease, kidney disease and blindness. So when you support the American Diabetes Association, you fight some of the worst diseases of our time.



B-D *MICRO-FINE III* Unequalled Injection Comfort.

*The thinnest, finest, sharpest
needle ever made!*



No other Insulin Syringe can match it.

The more often you inject insulin, the more you'll appreciate the remarkable B-D MICRO-FINE III needle.

MICRO-FINE III doesn't mistreat your skin. Its finely-polished and lubricated point injects so gently you hardly feel it—if you feel it at all.

Perhaps that's why doctors, nurses and hospitals *use*—and pharmacists *recommend*—B-D insulin syringes over all other brands combined. No other syringe can match the overwhelming professional endorsement of B-D quality and reliability. B-D is in a class by itself.

New B-D LO-DOSE® 1/2cc Syringe Design

A new needle shield and plunger cap guarantee sterility.

Syringes can now be packed in convenient packs of ten, without the need for bulky outer packaging.


Toll-Free Information Number

You can talk with a B-D Professional about the use or performance of any B-D product. Just call toll-free 1-800-237-4554...9 a.m. to 5 p.m. (Eastern). Not for emergency or medical information.

BETTER B-D
DIABETES CARE

B-D, PLASTIPAK, LO-DOSE, and MICRO-FINE III are trademarks of Becton Dickinson and Company

Preserve your copies of DIABETES CARE.



Custom-made for DIABETES CARE, these journal slipcasses and binders turn back issues into a permanent reference source. Bound in attractive blue leatherette, and embossed with gold lettering, each slipcase and binder holds 1 year of DIABETES CARE (6 issues plus supplement). And each comes with gold transfers, allowing you to personalize your volume further. These durable, space saving cases make affordable gifts as well.

SLIPCASSES: \$7.95 each, three for \$21.95, six for \$39.95 (measures: 11½ × 8½ × 2¼")

BINDERS: \$9.95 each, three for \$27.95, six for \$52.95 (measures: 12¾ × 9¼ × 3½")

MAIL TO: Jesse Jones Industries, Dept. DIAB-C
499 East Erie Avenue, Philadelphia, PA 19134

Please send _____ cases; _____ binders.

Enclosed is \$_____. Add \$1 per item for Postage and Handling.
Outside U.S.A. add \$2.50 per item (U.S. funds only).

Print Name _____

Address _____

No P.O. Boxes Please

City/State/Zip _____

PA residents add 6% sales tax

We also accept American Express, Visa, MasterCard and Diners Club (for minimum orders of \$15.00). Call TOLL FREE (charge orders only) 1-800-972-5858, 7 days, 24 hours.

NOTE: Satisfaction guaranteed. Slipcase and binders are also available for DIABETES & DIABETES FORECAST.

For information write:

American Diabetes Association,
1660 Duke St., Alexandria, VA 22314,
Attn: Circulation Dept.



In mild to moderate hypertension

Brief Summary

THE FIRST ONCE DAILY CALCIUM CHANNEL BLOCKER

ISOPTIN® SR (verapamil HCl/Knoll) 240 mg scored, sustained-release tablets

CONTRAINDICATIONS: 1) Severe left ventricular dysfunction (see WARNINGS), 2) Hypotension (less than 90 mmHg systolic pressure) or cardiogenic shock, 3) Sick sinus syndrome or 2nd or 3rd degree AV block (except in patients with a functioning artificial ventricular pacemaker).

WARNINGS: Heart Failure: ISOPTIN should be avoided in patients with severe left ventricular dysfunction (see DRUG INTERACTIONS). Patients with milder ventricular dysfunction should, if possible, be controlled before verapamil treatment. Hypotension: ISOPTIN (verapamil HCl) may produce occasional symptomatic hypotension. Elevated Liver Enzymes: Elevations of transaminases with and without concomitant elevations in alkaline phosphatase and bilirubin have been reported. Periodic monitoring of liver function in patients receiving verapamil is therefore prudent. Accessory Bypass Tract (Wolff-Parkinson-White): Patients with paroxysmal and/or chronic atrial flutter or atrial fibrillation and a coexisting accessory AV pathway have developed increased antegrade conduction across the accessory pathway producing a very rapid ventricular response or ventricular fibrillation after receiving intravenous verapamil. While this has not been reported with oral verapamil, it should be considered a potential risk. Treatment is usually D.C.-cardioversion. Atrioventricular Block: The effect of verapamil on AV conduction and the SA node may cause asymptomatic 1st degree AV block and transient bradycardia. Higher degrees of AV block, while infrequent (0.8%), may require a reduction in dosage or, in rare instances, discontinuation of verapamil HCl. Patients with Hypertrophic Cardiomyopathy (IHSS): Although verapamil has been used in the therapy of patients with IHSS, severe cardiovascular decompensation and death have been noted in this patient population.

PRECAUTIONS: Impaired Hepatic or Renal Function: Verapamil is highly metabolized by the liver with about 70% of an administered dose excreted in the urine. In patients with impaired hepatic or renal function verapamil should be administered cautiously and the patients monitored for abnormal prolongation of the PR interval or other signs of excessive pharmacological effects (see OVERDOSAGE).

Drug Interactions: Beta Blockers: Concomitant use of ISOPTIN and oral beta-adrenergic blocking agents may be beneficial in certain patients with chronic stable angina or hypertension, but available information is not sufficient to predict with confidence the effects of concurrent treatment in patients with left ventricular dysfunction or cardiac conduction abnormalities. Digitalis: Clinical use of verapamil in digitalized patients has shown the combination to be well tolerated if digoxin doses are properly adjusted. However, chronic verapamil treatment increases serum digoxin levels by 50 to 75% during the first week of therapy and this can result in digitalis toxicity. Upon discontinuation of ISOPTIN (verapamil HCl), the patient should be reassessed to avoid underdigitalization. Antihypertensive Agents: Verapamil administered concomitantly with oral antihypertensive agents (e.g., vasodilators, angiotensin-converting enzyme inhibitors, diuretics, beta blockers, prazosin) will usually have an additive effect on lowering blood pressure. Patients receiving these combinations should be appropriately monitored. Disopyramide: Disopyramide should not be administered within 48 hours before or 24 hours after verapamil administration. Quinidine: In patients with hypertrophic cardiomyopathy (IHSS), concomitant use of verapamil and quinidine resulted in significant hypotension. There has been a report of increased quinidine levels during verapamil therapy. Nitrates: The pharmacologic profile of verapamil and nitrates as well as clinical experience suggest beneficial interactions. Cimetidine: Two clinical trials have shown a lack of significant verapamil interaction with cimetidine. A third study showed cimetidine reduced verapamil clearance and increased elimination to 1/2. Anesthetic Agents: Verapamil may potentiate the activity of neuromuscular blocking agents and inhalation anesthetics. Carbamazepine: Verapamil may increase carbamazepine concentrations during combined therapy. Rifampin: Therapy with rifampin may markedly reduce oral verapamil bioavailability. Lithium: Verapamil may lower lithium levels in patient on chronic oral lithium therapy. Carcinogenesis, Mutagenesis, Impairment of Fertility: There was no evidence of a carcinogenic potential of verapamil administered to rats for two years. Verapamil was not mutagenic in the Ames test. Studies in female rats did not show impaired fertility. Effects on male fertility have not been determined. Pregnancy (Category C): There are no adequate and well-controlled studies in pregnant women. ISOPTIN crosses the placental barrier and can be detected in umbilical vein blood at delivery. This drug should be used during pregnancy, labor, and delivery, only if clearly needed. Nursing Mothers: ISOPTIN is excreted in human milk, therefore, nursing should be discontinued while verapamil is administered. Pediatric Use: Safety and efficacy of ISOPTIN in children below the age of 18 years have not been established.

ADVERSE REACTIONS: Constipation 8.4%, dizziness 3.5%, nausea 2.7%, hypotension 2.5%, edema 2.1%, headache 1.9%, CHF/pulmonary edema 1.8%, fatigue 1.7%, bradycardia 1.4%, 3° AV block 0.8%, flushing 0.1%, elevated liver enzymes (see WARNINGS). The following reactions, reported in less than 1.0% of patients, occurred under conditions (open trials, marketing experience) where a causal relationship is uncertain; they are mentioned to alert the physician to a possible relationship: angina pectoris, arthralgia and rash, AV block, blurred vision, cerebrovascular accident, chest pain, claudication, confusion, diarrhea, dry mouth, dyspnea, ecchymosis or bruising, equilibrium disorders, exanthema, gastrointestinal distress, gingival hyperplasia, gynecomastia, hair loss, hyperkeratosis, impotence, increased urination, insomnia, macules, muscle cramps, myocardial infarction, palpitations, paresthesia, psychotic symptoms, purpura (vasculitis), shakiness, somnolence, spotty menstruation, sweating, syncope, urticaria. Treatment of Acute Cardiovascular Adverse Reactions: Whenever severe hypotension or complete AV block occur following oral administration of verapamil, the appropriate emergency measures should be applied immediately, e.g., intravenously administered isoproterenol HCl, levaterenol bitartrate, atropine (all in the usual doses), or calcium gluconate (10% solution). If further support is necessary, inotropic agents (dopamine or dobutamine) may be administered. Actual treatment and dosage should depend on the severity and the clinical situation and the judgment and experience of the treating physician.

OVERDOSAGE: Treatment of overdosage should be supportive. Beta-adrenergic stimulation or parenteral administration of calcium solutions may increase calcium ion flux across the slow channel, and have been used effectively in treatment of deliberate overdosage with verapamil. Clinically significant hypotensive reactions or fixed high degree AV block should be treated with vasopressor agents or cardiac pacing, respectively. Asystole should be handled by the usual measures including cardiopulmonary resuscitation.

Knoll Pharmaceuticals
A Unit of BASF K&F Corporation
Whippany, New Jersey 07981



BASF Group
©1986, BASF K&F Corporation

2474/11/86

Printed in U.S.A.

120

100

80

60

40

20

0

130

110

90

70

50


30

10

In mild to moderate hypertension

**THE FIRST
ONCE DAILY**

**CALCIUM
CHANNEL
BLOCKER...**




NEW
ONCE DAILY



ISOPTIN[®] SR^{*}

(verapamil HCl/Knoll)

240 mg scored, sustained-release tablets



JAMES B.
38, black male, heavy smoker. Prescribed a diuretic by another physician last year for hypertension.

YOUR CONCERNS
Presents with "smoker's cough." Workup reveals a BP of 150/107.

A LOGICAL CHOICE FOR CONTROL OF HIS BP
ISOPTIN[®] (verapamil HCl/Knoll) because...


- Black hypertensives often have low plasma renin activity and generally do not respond favorably to beta blockers.
- Beta blockers may increase the likelihood of bronchospasm.

ALICE W.
65, diabetic, overweight. Her BP has elevated to 190/98.

YOUR CONCERNS
She's on daily insulin.

A LOGICAL CHOICE FOR CONTROL OF HER BP
ISOPTIN[®] (verapamil HCl/Knoll) because...

- Unlike most beta blockers and diuretics, ISOPTIN has no adverse effects on serum glucose levels.
- Unlike most beta blockers, ISOPTIN does not mask the symptoms of hypoglycemia.



THOMAS G.
70, asthmatic. In the past, BP adequately controlled with 25 mg hydrochlorothiazide daily.

YOUR CONCERNS
Today patient presents with symptoms of gout. Workup reveals high uric acid level, low serum potassium, and BP elevated to 180/98.

A LOGICAL CHOICE FOR CONTROL OF HIS BP
ISOPTIN[®] (verapamil HCl/Knoll) because...


- Unlike diuretics, ISOPTIN will not decrease serum potassium levels or elevate uric acid levels.
- Unlike beta blockers, ISOPTIN can be used safely in asthma and COPD patients.

JOHN K.
42, Annual physical uncovered diastolic BP of 102... confirmed on three successive office visits. Unresponsive to nonpharmacologic intervention.

YOUR CONCERNS
Salesman, spends many hours of his working day in car... total cholesterol level 300, HDL 35.

A LOGICAL CHOICE FOR CONTROL OF HIS BP
ISOPTIN[®] (verapamil HCl/Knoll) because...

- Unlike diuretics, ISOPTIN does not cause urinary urgency.
- Unlike either beta blockers or diuretics, ISOPTIN will not adversely affect his already seriously compromised lipid profile.
- Unlike with propranolol, fatigue and impotence are rarely reported.



**Antihypertensive therapy you
and your patients can live with**

*A product of Knoll research.

© 1986, BASF K & F Corporation

2538/2-87

Knoll Pharmaceuticals
A Unit of BASF K&F Corporation
Whippany, New Jersey 07981

BASF Group



Printed in U.S.A.


Please see adjacent page for brief summary.

UNMISTAKABLY AHEAD OF THE REST

- Extremely accurate and reliable
- Most widely used system in hospitals¹
- Portable and easy to use
- Most often recommended by diabetologists and endocrinologists^{1*}

Accu-Chek II[®]

Blood Glucose Monitor



THE LINE OF CONFIDENCESM IN DIABETES CONTROL

For more information, please call toll-free 1-800-858-8072. Available at most retail pharmacies.

*From a group of physicians surveyed. Reference: 1. Data on file, Boehringer Mannheim Diagnostics. © 1987 Boehringer Mannheim Corporation. All rights reserved.

From Squibb-**NovoPen**® Insulin Delivery System

The Future of Human Insulin Delivery Is Here



The first comprehensive, streamlined human insulin delivery system

Designed for the lifestyle of your patients with diabetes

Convenient:

- Sleek fountain-pen design makes it lightweight and portable.
- Eliminates the need for conventional syringes and vials for Novolin® R Human Insulin (semi-synthetic).

Discreet:


- Unobtrusive carrying and handling of NovoPen® may encourage adherence to multiple daily injection regimens.
- Easy to administer insulin away from home.

Accurate:

- Push-button measurement designed for accurate delivery of two or more units of Novolin® R Insulin.
- Eliminates dosing errors that may result from visually estimating dose.

For further information about NovoPen®, call 1-800-334-3678. In New Jersey, call 1-800-367-0249.

NovoPen® bringing new simplicity and convenience to life with diabetes.



SQUIBB®
NOVO™ The diabetes care specialists